Liminatus Pharma, Inc.
LIMNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $90.1K in total; no superinvestor holds it.
Other share classesLIMN
Q3 2025 vs. Q2 2025
How the institutions holding Liminatus Pharma, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 27 | +2 |
| Shares | 3.43M | 805.5K | 2.64M | +16.1K (+0.6%) |
| Value | $837.0K | $193.2K | $400.3K | −$243.4K (−37.8%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Liminatus Pharma, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Clear Street Group Inc. | 805,377 | $119.1K | 0.00% |
| Nomura Holdings Inc | 97,325 | $11.7K | 0.00% |
| GTS Securities LLC | 30,000 | $4.44K | 0.00% |
Sold out (1)
Institutions that held Liminatus Pharma, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Cantor Fitzgerald, L. P. | 875,817 | $210.1K |
Not filed for Q3 2025 yet (1)
Institutions that held Liminatus Pharma, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Clear Street LLC | 805,477 | $193.2K |